Skip to main content
. 2015 Jan 22;15:7. doi: 10.1186/s12913-014-0640-z

Table 4.

Psychometric properties of selected health utilities measures in HIV population

Tools HIV/AIDS population Reliability Validity Longitudinal validity Floor Ceiling
Subjects Country Sample size ICR TTR Construct Criterion (concurrent) Sensitivity Responsiveness
Convergent Other measures HIV clinical signs Other clinical characteristic
EQ-5D-3L* HIV+ patient [18,26-46] Developing [37-39,41,46] 16-2261 0.81-0.86 [39] 0.78 [18] MOS-HIV [27] SF36 (r =  0.55-0.74) [18] CD4 count [18,28,38] HIV stages [29,36] Improve over time [30] Decline after diagnosis of AE [26,27,35,40] 0.0 [18,26-28,37,47] 12.4 - 39.7 [18,26-28,32,37,47]
SF6D (r =  0.74) [18] GBV-C status [31]
ART* status [33] Decline after health status worse [18]
WHOQOL-BREF (r =  0.31-0.60) [37]
SAE status [34] Decline after CD4 and VL decline [32]
AQOL (r =  0.539) [41] Viral load [28] CD4 count group [32,37]
Developed [18,26-36,40,42-45,47] HUI3 (r = 0.551) [41] Improve when CD4 improve [38]
VAS (r = 0.41-0.80) [18,28,29,39]
Viral load group [32] Decline before and after diagnosis of SAE* [35,40]
MOS-HIV (r = 0.40-0.72) [26,28,29,32,47]
EQ-5D-5L* HIV+ patients [48] Developing [48] 1016 0.85 [48] - - VAS (r = 0.73) [48] HIV stages [48] - -
CD4 count group [48]
Global rating of HRQoL (r = 0.36) [48]
Duration of ART [48]
15D HIV+ patients [18] Developed [18] 60 - 0.9 [18] - SF36 (r =  0.59-0.80) [18] CD4 count [18] Change follow the change of health status [18] 0 [18] 10-12 [18]
VAS (r = 0.73) [18] Viral load [18]
HUI2* HIV+ patients [34] Developed [34] 57 - - - - - - -
HUI3* HIV+ patient [26,35,40,41,49] Developing [41] 57-1200 - - - MOS-HIV (r = 0.34-0.70) [26,47] CD4 count [35,40,49] Decline after diagnosis of AE* [26] 0-3.2 [26,47] 3.15-5.4 [26,47]
Developed [26,35,40,47,49] AQOL (r =  0.543) [41] Viral load [40] Decline before and after diagnosis of SAE* [35,40]
EQ-5D-3L (r = 0.551) [41]
SF-6D* HIV+ patients [4,18,50] Developed [4,18,50-52] 55-2508 - 0.94 [18] - SF36 (r = 0.73-0.79) [18] - - Change follow the change of health status [18] 0 [18] 6-10 [18]
HIV+
women [51] VAS (r = 0.75) [18]
HIV+ IDUs [52]
SG* HIV+ patients [4,6,17,26,37,40,53-56] Developing [17,37,55] 75-450 - 0.41-0.42 [17] - TTO (r =  0.21-0.39) [17] CD4 count groups [26,37,53] - Decline after diagnosis of SAE* [40] 7.6-11 [26,37,47] 0.8-22 [26,37,47]
VAS (r = 0.26-0.34) [17]
MOS-HIV (r = 0.14-0.15) [26,47]
Developed [4,6,26,40,47,53,54,56]
WHOQOL-BREF (r =  0.09-0.34) [37] HIV stages [4]
Global rating of change [17]
TTO* HIV+ patients [6,17,26,40,53,54,56,57] Developing [17] 66-450 - 0.71-0.83 [17] - Global rating of change [53] CD4 count [40] CD4 count group [26,53] Improve over time [17] Decline after diagnosis of SAE* [40] 4.4 [26,47] 18.3 [26,47]
SG (r =  0.21-0.39) [17]
Developed [6,26,40,47,53,54,56,57] VAS (r =  0.45-0.61) [17]
MOS-HIV (r = 0.21-0.29) [26,47]
VAS* HIV+ patient [4,6,17,26-30,37,39,40,42,44-46,48,53,54,56,58-71] Developing [17,37,39,46,58,63,71] 16-2865 - 0.71-0.83 [17] MOS-HIV [27] Global rating of change [17] CD4 count [28,40,61,64] HIV stages [4,29] Improve over time [58] Decline after diagnosis of AE* [26,27] and OI* [27] 0-2 [18,26-28,37,47] 3.3-10.8 [18,26-28,37,47]
MOS-HIV (r = 0.33-0.72) [26,28,29,47,63]
EQ-5D-3L (r = 0.41-0.63) [28,29,39] CD4 count groups [37,53]
EQ-5D-5L (r = 0.73) [48]
Developed [4,6,26-30,34,40-42,44,45,47,53,54,56,60,61,64-70] HIV-RNA groups [64]
SG (r = 0.26-0.34) [17] Viral load [28,64] Decline before and after diagnosis of SAE* [40,64]
TTO (r = 0.45-0.61) [17]
WHOQOL-BREF (r =  0.36-0.54) [37]

*EQ-5D-3L: EuroQol −5 dimensions-3 levels; EQ-5D-5L: EuroQol −5 dimensions-5 levels; HUI2: Health utility index 2; HUI3: health utility index 3; SF-6D: Short form 6-dimensions; SG: standard gamble; TTO: time trade-off; VAS: visual analogue scale; ART: Antiretroviral therapy; VL: viral load; AE: Adverse events; ADE: AIDS defining events; OI: Opportunistic infection; SAE: serious adverse events.